Intervention not reported
No active intervention · people with liver cirrhosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Norfloxacin + neomycin (1 RCT, 22 participants) · people with liver cirrhosis
The intervention may leads to lower norfloxacin + neomycin (1 RCT, 22 participants) (low certainty).
1 finding from 1 review
Intervention not reported
Norfloxacin + rifaximin (no direct RCT) · people with liver cirrhosis
It is very uncertain whether the intervention changes norfloxacin + rifaximin (no direct RCT) (very low certainty).
1 finding from 1 review
Intervention not reported
Rifaximin (3 RCTs, 575 participants) · people with liver cirrhosis
The intervention may leads to lower rifaximin (3 RCTs, 575 participants) (low certainty).
1 finding from 1 review
Intervention not reported
Norfloxacin (3 RCTs, 439 participants) · people with liver cirrhosis
It is very uncertain whether the intervention changes norfloxacin (3 RCTs, 439 participants) (very low certainty).
1 finding from 1 review
Intervention not reported
Rifaximin (3 RCTs, 479 participants) · people with liver cirrhosis
It is very uncertain whether the intervention changes rifaximin (3 RCTs, 479 participants) (very low certainty).
1 finding from 1 review
HR 0.57 [0.33, 1]
Studies not reported
Very low
Intervention not reported
Norfloxacin (4 RCTs, 546 participants) · people with liver cirrhosis
It is very uncertain whether the intervention changes norfloxacin (4 RCTs, 546 participants) (very low certainty).
1 finding from 1 review
HR 0.74 [0.49, 1.09]
Studies not reported
Very low
Intervention not reported
Ciprofloxacin (3 RCTs, 255 participants) · people with liver cirrhosis
It is very uncertain whether the intervention changes ciprofloxacin (3 RCTs, 255 participants) (very low certainty).
1 finding from 1 review
HR 0.61 [0.31, 1.16]
Studies not reported
Very low
Intervention not reported
Norfloxacin +rifaximin (no direct RCT) · people with liver cirrhosis
It is very uncertain whether the intervention changes norfloxacin +rifaximin (no direct RCT) (very low certainty).
1 finding from 1 review
HR 0.4 [0.12, 1.17]
Studies not reported
Very low
Intervention not reported
Rufloxacin (no direct RCT) · people with liver cirrhosis
It is very uncertain whether the intervention changes rufloxacin (no direct RCT) (very low certainty).
1 finding from 1 review
HR 1.45 [0.27, 8.21]
Studies not reported
Very low
Intervention not reported
Rifaximin (2 RCTs, 353 participants) · people with liver cirrhosis
It is very uncertain whether the intervention changes rifaximin (2 RCTs, 353 participants) (very low certainty).
1 finding from 1 review
Intervention not reported
Interventions · adults undergoing liver transplantation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Basiliximab (1 RCT; 47 participants) · adults undergoing liver transplantation
The intervention may leads to lower basiliximab (1 RCT; 47 participants) (low certainty).
1 finding from 1 review
HR 0.44 [0.28, 0.7]
Studies not reported
Low
Intervention not reported
Daclizumab plus glucocorticosteroids (3 RCTs; 927 participants) · adults undergoing liver transplantation
It is very uncertain whether the intervention changes daclizumab plus glucocorticosteroids (3 RCTs; 927 participants) (very low certainty).
1 finding from 1 review
HR 1.27 [0.49, 3.75]
Studies not reported
Very low
Intervention not reported
Anti‐thymocyte globulin (1 RCT; 119 participants) · adults undergoing liver transplantation
It is very uncertain whether the intervention changes anti‐thymocyte globulin (1 RCT; 119 participants) (very low certainty).
1 finding from 1 review
HR 0.89 [0.21, 3.88]
Studies not reported
Very low
Intervention not reported
No active intervention (only maintenance immunosuppression) (1 RCT; 45 participants) · adults undergoing liver transplantation
It is very uncertain whether the intervention changes no active intervention (only maintenance immunosuppression) (1 RCT;… (very low certainty).
1 finding from 1 review
HR 0.76 [0.12, 4.59]
Studies not reported
Very low
Intervention not reported
Health‐related quality of life · adults undergoing liver transplantation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Basiliximab plus glucocorticosteroids (2 RCTs; 528 participants) · adults undergoing liver transplantation
It is very uncertain whether the intervention changes basiliximab plus glucocorticosteroids (2 RCTs; 528 participants) (very low certainty).
1 finding from 1 review
OR 1 [0.67, 1.47]
Studies not reported
Very low
Intervention not reported
Daclizumab plus glucocorticosteroids (2 RCTs; 897 participants) · adults undergoing liver transplantation
It is very uncertain whether the intervention changes daclizumab plus glucocorticosteroids (2 RCTs; 897 participants) (very low certainty).
1 finding from 1 review
OR 0.87 [0.65, 1.15]
Studies not reported
Very low
Intervention not reported
Anti‐thymocyte globulin plus glucocorticosteroids (1 RCT; 37 participants) · adults undergoing liver transplantation
It is very uncertain whether the intervention changes anti‐thymocyte globulin plus glucocorticosteroids (1 RCT; 37… (very low certainty).
1 finding from 1 review